Clivunel Inc Drug Patent Portfolio
Clivunel Inc owns 1 orange book drug protected by 2 US patents Given below is the list of Clivunel Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8334265 | Method of treatment of photodermatoses | 11 Mar, 2029 | Active |
| US10076555 | Methods of inducing melanogenesis in a subject | 11 Feb, 2025 | Active |
Latest Legal Activities on Clivunel Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Clivunel Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 10 Jun, 2024 | US8334265 |
|
Patent Term Extension Certificate
Critical
| 25 May, 2023 | US8334265 |
| Notice of Final Determination -Eligible | 17 Apr, 2023 | US8334265 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US8334265 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 Mar, 2022 | US10076555 |
| transaction for FDA Determination of Regulatory Review Period | 04 Nov, 2021 | US8334265 |
| transaction for FDA Determination of Regulatory Review Period | 22 Oct, 2021 | US8334265 |
| Second letter to regulating agency to determine regulatory review period | 31 Mar, 2021 | US8334265 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 Jun, 2020 | US8334265 |
| Letter from FDA or Dept of Agriculture re PTE application | 26 May, 2020 | US8334265 |
| Initial letter Re: PTE Application to regulating agency | 26 Feb, 2020 | US8334265 |
|
Email Notification
Critical
| 10 Jun, 2019 | US8334265 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Jun, 2019 | US8334265 |
|
Correspondence Address Change
Critical
| 06 Jun, 2019 | US8334265 |
|
Recordation of Patent Grant Mailed
Critical
| 18 Sep, 2018 | US10076555 |
Clivunel Inc's Family Patents
Clivunel Inc Drug List
Given below is the complete list of Clivunel Inc's drugs and the patents protecting them.
1. Scenesse
Scenesse is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8334265 | Method of treatment of photodermatoses |
11 Mar, 2029
(4 years from now)
| Active |
| US10076555 | Methods of inducing melanogenesis in a subject |
11 Feb, 2025
(a month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Scenesse's drug page